[go: up one dir, main page]

AU1201797A - Nebulizer - Google Patents

Nebulizer

Info

Publication number
AU1201797A
AU1201797A AU12017/97A AU1201797A AU1201797A AU 1201797 A AU1201797 A AU 1201797A AU 12017/97 A AU12017/97 A AU 12017/97A AU 1201797 A AU1201797 A AU 1201797A AU 1201797 A AU1201797 A AU 1201797A
Authority
AU
Australia
Prior art keywords
nebulizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12017/97A
Inventor
Surinderjit Kumar Jassell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intersurgical Ltd
Original Assignee
Intersurgical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intersurgical Ltd filed Critical Intersurgical Ltd
Publication of AU1201797A publication Critical patent/AU1201797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nozzles (AREA)
AU12017/97A 1995-12-20 1996-12-20 Nebulizer Abandoned AU1201797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9526100A GB9526100D0 (en) 1995-12-20 1995-12-20 Nebulizer
GB9526100 1995-12-20
PCT/GB1996/003201 WO1997022376A1 (en) 1995-12-20 1996-12-20 Nebulizer

Publications (1)

Publication Number Publication Date
AU1201797A true AU1201797A (en) 1997-07-14

Family

ID=10785782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12017/97A Abandoned AU1201797A (en) 1995-12-20 1996-12-20 Nebulizer

Country Status (4)

Country Link
EP (1) EP0959925A1 (en)
AU (1) AU1201797A (en)
GB (1) GB9526100D0 (en)
WO (1) WO1997022376A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
JP2007528691A (en) 2001-11-14 2007-10-18 セントカー・インコーポレーテツド Anti-IL-6 antibodies, compositions, methods and uses
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
UA89481C2 (en) 2003-09-30 2010-02-10 Центокор, Инк. Human epo mimetic hinge core mimetibodies, compositions, methods and uses
AU2005231359A1 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PE20061324A1 (en) 2005-04-29 2007-01-15 Centocor Inc ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES
TR201902033T4 (en) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and uses.
PL3219328T3 (en) 2005-12-29 2020-12-14 Janssen Biotech, Inc Human anti-il-23 antibodies, compositions, method and uses
JP2010500360A (en) 2006-08-10 2010-01-07 アルボア コーポレーション Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors
AR064623A1 (en) 2006-12-21 2009-04-15 Centocor Inc USE OF LONG-TERM GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES
EP2326668B1 (en) 2008-08-14 2018-01-17 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/il-23 antibodies
US8278419B2 (en) 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
CN102596992B (en) 2009-02-12 2015-09-09 詹森生物科技公司 Based on the holder combination thing of III type fibronectin domain, method and purposes
KR20130009760A (en) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Cd20 antibodies and uses thereof
AU2011268110B2 (en) 2010-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Anti-GD2 antibodies
TWI726291B (en) 2013-01-07 2021-05-01 英屬維爾京群島商遠東超級實驗室有限公司 Methods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon
RU2680267C2 (en) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер High-affinity anti-gd2 antibodies
WO2018140026A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN115368460A (en) 2015-03-17 2022-11-22 纪念斯隆-凯特林癌症中心 Anti-MUC16 antibody and its application
RU2019104075A (en) 2016-07-15 2020-08-17 Посейда Терапьютикс, Инк. CHIMERIC ANTIGEN RECEPTORS (CAR) SPECIFIC FOR MUC1 AND METHODS OF THEIR APPLICATION
BR112019000683A2 (en) 2016-07-15 2019-04-24 Poseida Therapeutics Inc chimeric antigen receptors and methods for use
KR20190113858A (en) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Psoriatic Arthritis
MA47442A (en) 2017-02-07 2019-12-18 Janssen Biotech Inc ANTI-TNF ANTIBODIES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLARTHRITIS
KR102752985B1 (en) 2017-12-20 2025-01-10 포세이다 테라퓨틱스, 인크. VCAR Composition and Method of Use
WO2019215701A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
KR20210116540A (en) 2019-01-15 2021-09-27 얀센 바이오테크 인코포레이티드 Anti-TNF antibody compositions and methods for the treatment of juvenile idiopathic arthritis
AU2020210962A1 (en) 2019-01-23 2021-07-22 Janssen Biotech, Inc. anti-TNF antibody compositions for use in methods for the treatment of Psoriatic Arthritis
JP2022524860A (en) 2019-03-14 2022-05-10 ヤンセン バイオテツク，インコーポレーテツド Methods for Producing Anti-TNF Antibody Compositions
MA55283A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
KR20210142002A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Methods of Preparation for Producing Anti-TNF Antibody Compositions
JP2022534020A (en) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Methods of treating inflammatory bowel disease with combination therapy of antibodies against IL-23 and TNF-alpha
JP2022536279A (en) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド Anti-TNF antibody compositions and methods for treating psoriatic arthritis
AU2020288404A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
BR112022020650A2 (en) 2020-04-14 2023-01-31 Poseida Therapeutics Inc COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF CANCER
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
US20230312684A1 (en) 2020-07-31 2023-10-05 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
WO2023279115A1 (en) 2021-07-02 2023-01-05 Henry Ford Health System Compositions comprising endosidin 2 for reducing sars-cov-2 infection
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
JP2024526315A (en) 2021-07-09 2024-07-17 ヤンセン バイオテツク，インコーポレーテツド Method for producing anti-TNF antibody composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001731A1 (en) * 1984-09-18 1986-03-27 Vortran Corporation All purpose nebulizer
DE3775679D1 (en) * 1986-09-22 1992-02-13 Omron Tateisi Electronics Co MISTAKER.
DE3636669C2 (en) * 1986-10-28 2001-08-16 Siemens Ag Arrangement for delivering aerosol to a patient's airways and / or lungs
US5301662A (en) * 1991-09-25 1994-04-12 Cimco, Inc. Nebulizer with high oxygen content and high total flow rate

Also Published As

Publication number Publication date
GB9526100D0 (en) 1996-02-21
EP0959925A1 (en) 1999-12-01
WO1997022376A1 (en) 1997-06-26

Similar Documents

Publication Publication Date Title
AU1201797A (en) Nebulizer
AU5235796A (en) o-hydroxyphenyl-s-triazines
AU4780896A (en) Core-board
AU6000496A (en) Phenylpyridazinones
AU6304196A (en) Substituted cyanophenyluracils
AU5896396A (en) Pyridine-microbicides
AU1030997A (en) Taphane
AU2501195A (en) Nebulizer
AU4996696A (en) 2-benzyl-3-arylbenzothiophenes
AU5147496A (en) Fucopeptides
AU5593896A (en) Benzisothiazolyl-substituted aminomethylchromans
AU6235496A (en) Azothiophenes
AU5500196A (en) Anti-transpirants
AU4382896A (en) Acetylimidazobenzodiazepines
AU6304396A (en) Substituted carbonylaminophenyluracils
AU5108596A (en) Morphine-3-esters
AU5917896A (en) Poly-beta-1-4-N-acetylglucosamine
AU6215196A (en) Piperidinylmethyloxazolidinones
AU5013796A (en) Wireclamp
AU5107096A (en) Haemodialyser
AUPN649195A0 (en) Vaporiser
AU4569496A (en) Tetralinyl- and indanyl-ethylamides
AU4482596A (en) Atomizer
AU6658696A (en) Substituted phenyluracils
AU6658396A (en) Polyhydroxyalkylamidobetaine